Orexigen Therapeutics Free Cash Flow
Orexigen Therapeutics Historical Free Cash Flow Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2010 | -7.18M |
| Sept. 30, 2010 | 38.23M |
| June 30, 2010 | -10.89M |
| March 31, 2010 | -14.44M |
| Dec. 31, 2009 | -13.76M |
| Sept. 30, 2009 | -18.15M |
| June 30, 2009 | -16.63M |
| March 31, 2009 | -20.12M |
| Dec. 31, 2008 | -17.85M |
About Free Cash Flow
Free cash flow is the amount of cash generated by a business that is available for distribution among its security holders. Security holders include debt holders, equity holders, preferred stock holders, and convertible security holders. Specifically, free cash flow is used to pay dividends, make acquisitions, develop new products, invest in new property, plant and equipment, pay interest expenses, and reduce debt.
According to many investors, free cash flow is the best indication of a company's ability to generate cash.
Learn More
OREX Free Cash Flow Benchmarks
| Companies | |
|---|---|
| Arena Pharmaceuticals | -9.781M |
| Vivus | -59.43M |
| Sucampo Pharmaceuticals | 17.04M |
OREX Free Cash Flow Range, Past 5 Years
| Minimum | -22.46M | Sep 2008 |
| Maximum | 38.23M | Sep 2010 |
| Average | -10.89M |
